Home » Stocks » EGRX

Eagle Pharmaceuticals, Inc. (EGRX)

Stock Price: $40.43 USD -0.19 (-0.47%)
Updated May 6, 2021 4:00 PM EDT - Market closed
Market Cap 536.94M
Revenue (ttm) 187.80M
Net Income (ttm) 11.99M
Shares Out 13.48M
EPS (ttm) 0.87
PE Ratio 46.47
Forward PE 12.22
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $40.43
Previous Close $40.62
Change ($) -0.19
Change (%) -0.47%
Day's Open 40.55
Day's Range 40.16 - 40.87
Day's Volume 71,270
52-Week Range 36.48 - 56.16

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 days ago - Zacks Investment Research

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the appointment of Luciana (“Lu”) Borio, MD, to its Board of Directors. Dr. B...

3 days ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that TREAKISYM ready-to-dilute (“RTD”) (bendamustine hydrochloride 120 mg/m2)...

6 days ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 first quarter financial results on Mon...

1 week ago - Business Wire

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 323.26% and -0.32%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share increased 100.00% year over year to $0.96, which may not com...

2 months ago - Benzinga

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and twelve months ended December 31, 2020, an...

2 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 fourth quarter and full year financial...

2 months ago - Business Wire

The FDA has issued a complete response letter (CRL) for Eagle Pharmaceuticals Inc's (NASDAQ: EGRX) abbreviated marketing application seeking vasopressin approval.

3 months ago - Benzinga

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete resp...

3 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that, on January 29, 2021, the United States District Court for the District ...

3 months ago - Business Wire

NEWARK, N.J., Jan. 28, 2021 /PRNewswire/ -- SEEDS – Access Changes Everything (SEEDS) is pleased to announce a new, multi-year partnership with Eagle Pharmaceuticals that will provide educational fundin...

3 months ago - PRNewsWire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that, on January 8, 2021, the United States District Court for the District o...

3 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financia...

4 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company's pre-recorded presentation at the Piper Sandler 32nd Annual...

5 months ago - Business Wire

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 303.45% and 7.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and nine months ended September 30, 2020. Bus...

6 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced four additions to its clinical, formulations and commercialization leadership...

6 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 third quarter financial results on Mon...

6 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that its Board of Directors has approved a $25 million accelerated share repu...

7 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that its marketing partner, SymBio Pharmaceuticals Limited (“SymBio”), has re...

7 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc.

7 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc.

8 months ago - Business Wire

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 307.14% and 11.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) were flat in pre-market trading after the company reported Q2 results.

8 months ago - Benzinga

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc.

8 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc.

9 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that the Centers for Medicare & Medicaid Services (CMS) has established a uni...

9 months ago - Business Wire

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 78.72% and -3.63%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) remained unaffected at $55.02 after the company reported Q1 results.

11 months ago - Benzinga

Eagle Pharmaceuticals (EGRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

11 months ago - Zacks Investment Research

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Eagle Pharmaceuticals stock popped Thursday after the pharmaceutical company said its hyperthermia drug, Ryanodex, showed promise as a potential coronavirus treatment in a laboratory test. The post Cov...

1 year ago - Investors Business Daily

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 37.14% and 8.45%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -16.13% and -5.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 16.67% and 10.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 77.19% and 12.43%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 years ago - Zacks Investment Research

About EGRX

Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and m... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Feb 12, 2014
CEO
Scott Tarriff
Employees
106
Stock Exchange
NASDAQ
Ticker Symbol
EGRX
Full Company Profile

Financial Performance

In 2020, EGRX's revenue was $187.80 million, a decrease of -4.13% compared to the previous year's $195.89 million. Earnings were $11.99 million, a decrease of -16.24%.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for EGRX stock is "Buy." The 12-month stock price forecast is 48.00, which is an increase of 18.72% from the latest price.

Price Target
$48.00
(18.72% upside)
Analyst Consensus: Buy